3D Tissue Models
Imaging in Cancer Drug Development
Copthorne Tara Hotel

London, United Kingdom

   • Helen Young, Imaging Specialist, AstraZeneca

   • Jan Passchier, Director, PET and Radiochemistry, GlaxoSmithKline •
   Werner Scheuer, Group Leader, Preclinical Optical Imaging,
   Pharmacology TR-PD, Pharmaceutical Research, Roche • Rainer Kneuer,
   Investigator III , Novartis Institutes for Biomedical Research

   SMi is proud to present the 7th annual conference in its series on
   imaging for the purposes of developing novel cancer therapies. Imaging
   in Cancer Drug Development will build on the success of the previous 6
   years to bring your knowledge in this field in line with the latest

   Taking place in central London, UK, you will hear presentations from
   the key players in the cancer and imaging arena. The conference will
   focus on a wide range of imaging techniques in a wide range of
   settings – from the preclinical, to the clinical, to the future of
   oncological imaging. You will hear presentations from the leading
   experts in their fields on the latest developments in MRI , PET ,
   SPECT , IR and more. Attend this event and learn how best to use
   imaging techniques to expedite your oncology drug development process.
   Key topics covered by the conference include: • New techniques: the
   latest in new techniques and procedures for MRI , PET , SPECT and Mass
   Spectrometry • Clinical imaging with a focus on breast cancer •
   Preclinical imaging with a view to developing personalised cancer
   therapies • Future developments and improving the safety of imaging
   Challenges of Using Imaging in Oncology Clinical Trials 9th March
   2011, Copthorne Tara Hotel, London In association with Nexus Oncology

Schedule of Presentations:

Monday, March 7, 2011
08:30:00 Registration & Coffee
09:00:00 Chairman's Opening Remarks
09:10:00 Assessing objective treatment response in oncology: RECIST and beyond
09:50:00 The role of PET in drug development Jan Passchier
10:30:00 Morning Coffee
11:00:00 Monitoring reviewer metrics during independent central review (ICR)
11:40:00 Preclinical SPECT/CT and PET/CT Lefteris Livieratos
12:20:00 Networking Lunch
13:50:00 New biomarker development Simon Walker-Samuel
14:30:00 Application of different imaging modalities in the drug development process Werner Scheuer,
15:10:00 Afternoon Tea
15:40:00 Optical imaging agents and technologies used to study biologics and delivery vehicles in a tumour environment Rainer Kneuer
16:20:00 Preclinical imaging applied to cancer biology and drug development studies William Gallagher
17:00:00 Chairman’s Closing Remarks and Close of Day One
Tuesday, March 8, 2011
08:30:00 Registration & Coffee
09:00:00 Morning Chairman's Opening Remarks Rainer Kneuer
09:10:00 CT, MRI and PET for phase II/III with RECIST endpoints
09:50:00 Imaging of cancer and anti-cancer agents in vivo and ex vivo Geoff Boxer
10:30:00 Morning Coffee
11:00:00 Contrast-Enhanced Ultrasound (CEUS) Imaging Modality for the Evaluation of Angiogenesis Inhibitors Therapy Daniela Bokor
11:40:00 Biomarker investigation via stable isotope labelling and mass spectrometry of non-small lung cancer serum Gabriela Grigorean
12:20:00 Networking Lunch
13:50:00 Volumetric analysis of lesions in CT, MR and PET data Volker Dicken
14:30:00 Nanoparticles in imaging Peter King
15:10:00 Afternoon Tea
15:40:00 Imaging for global trials
16:20:00 Existing and novel PET tracers for monitoring and predicting response to treatment Adriaan Lammertsma
17:00:00 Chairman’s Closing Remarks and Close of Day Two
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.